(4-氯-苄基)-膦酸 | 39225-05-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氯-苄基)-膦酸
• 英文名称: p-Chlorbenzylphosphonsaeure
• 英文别名: 4-chlorobenzylphosphonic acid；(4-Chloro-benzyl)-phosphonic acid；(4-chlorophenyl)methylphosphonic acid
• CAS: 39225-05-3
• 化学式: C₇H₈ClO₃P
• 分子量: 206.565
• InChiKey: KFNFQPHCXKFJDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090

反应信息

• 作为产物：
  描述：

  4-氯苯基磷酸二乙酯 在 盐酸 作用下， 生成 (4-氯-苄基)-膦酸
  参考文献：
  名称：

  Williams,A. et al., Journal of the Chemical Society. Perkin transactions II, 1973, p. 25 - 33

  摘要：

  DOI：

文献信息

• AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：EP2634170A1

  公开（公告）日：2013-09-04

  A compound is shown by the following formula (1). wherein I, m, and n are independently an integer from 1 to 3, Ar1 to Ar4 are independently a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroaryl group having 5 to 30 ring atoms, Ar5, Ar6, and Ar7 are independently a substituted or unsubstituted arylene group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroarylene group having 5 to 30 ring atoms, and p is an integer from 0 to 2, and Ar6 and N are bonded via a single bond when p is 0, provided that at least one of Ar1 to Ar4 is substituted with a substituted silyl group, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms, and at least one of Ar1 to Ar4 is substituted with a cyano group.

  公式（1）显示了一个化合物，其中I、m和n分别是从1到3的整数，Ar1到Ar4分别是具有6到30个环碳原子的取代或未取代芳基基团，或者是具有5到30个环原子的取代或未取代杂芳基基团，Ar5、Ar6和Ar7分别是具有6到30个环碳原子的取代或未取代芳撑基团，或者是具有5到30个环原子的取代或未取代杂芳撑基团，p是从0到2的整数，当p为0时，Ar6和N通过单键结合，前提是Ar1到Ar4中至少有一个被取代为取代硅基基团、具有1到20个碳原子的取代或未取代烷基基团，或者具有3到10个碳原子的取代或未取代环烷基基团，而Ar1到Ar4中至少有一个被取代为氰基。
• Benzamide derivative
  申请人：Koyano Hiroshi

  公开号：US20070123493A1

  公开（公告）日：2007-05-31

  To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the compounds, intermediate compounds useful for their production, and pharmaceutical compositions containing these compounds. The present invention provides compounds of formula (II), or prodrugs thereof, or pharmaceutically acceptable salts of the compounds or the prodrugs, and pharmaceuticals, and pharmaceutical compositions containing these compounds: where A 1 is C—X 1 or N; Q 1 is —A 2 ═A 3 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is —A 4 ═A 5 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 1-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 1-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:

  提供具有高抑制血管生成活性的化合物，可用作治疗和预防涉及病理性血管生成的疾病的药物，例如癌症和癌症转移，以及生产这些化合物的方法，用于它们的生产的中间体化合物，以及含有这些化合物的药物组合物。本发明提供以下化合物的配方（II），或其前药，或该化合物或前药的药学上可接受的盐，以及含有这些化合物的药物和药物组合物：其中A1为C-X1或N; Q1为-A2═A3-，或从-O-，-S-和-N（R10）中选择的杂原子; Q2为-A4═A5-，或从-O-，-S-和-N（R10）中选择的杂原子; 前提是Q1和Q2不同时为杂原子; A2为C-X2或N，A3为C-X3或N，A4为C-X4或N，A5为C-X5或N; Y为C1-6烷基，C3-9环烷基，C2-7烯基，C2-7炔基，C1-6烷氧基，C2-7烯氧基，C2-7炔氧基或C1-6烷硫基; Z为氢原子，羟基，C1-6烷基，C3-9环烷基或-NR1R2; L从以下公式中选择：
• Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product
  申请人：Kageyama Katsuhiko

  公开号：US20080249280A1

  公开（公告）日：2008-10-09

  This invention provides a polyester and a polyester molded product, which, while maintaining color tone, transparency, and thermal stability, can realize a high polycondensation rate, are less likely to cause the production of polycondensation catalyst-derived undesired materials, and can simultaneously meet both quality and cost effectiveness requirements, which can exhibit the characteristic features, for example, in the fields of ultrafine fibers, high transparent films for optical use, or ultrahigh transparent molded products. These advantages can be realized by using, in the production of a polyester in the presence of an aluminum compound-containing polyester polycondensation catalyst, an aluminum compound having an absorbance of not more than 0.0132 as measured in the form of an aqueous aluminum compound solution, prepared by dissolving the aluminum compound in pure water to give a concentration of 2.7 g/liter in terms of the amount of aluminum element, under conditions of cell length 1 cm and wavelength 680 nm.

  本发明提供了一种聚酯和聚酯成型产品，可以在保持色调、透明度和热稳定性的同时，实现高聚酯化速率，不太可能引起聚酯化催化剂来源的不良材料的生产，并且可以同时满足质量和成本效益的要求，这些优点可以在超细纤维、用于光学的高透明薄膜或超高透明成型产品等领域展现出特征性能。通过在含有铝化合物聚酯聚合催化剂的聚酯生产中使用具有吸光度不超过0.0132的铝化合物，可以实现这些优点。该吸光度是在细胞长度为1厘米，波长为680纳米的条件下，将铝化合物溶解在纯水中以给定铝元素量浓度为2.7克/升形成的水溶性铝化合物溶液中测量得出的。
• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100041686A1

  公开（公告）日：2010-02-18

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I式，其中R1、R2、X、Y和n在说明书中定义，并且其药学上可接受的酸盐。本发明还提供了制备这些化合物的药物组合物和方法。这些化合物可用于治疗与微量胺相关受体的生物功能相关的疾病，该类疾病包括抑郁症、焦虑症、双相障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• BENZAMIDE DERIVATIVE
  申请人：KOYANO Hiroshi

  公开号：US20100179326A1

  公开（公告）日：2010-07-15

  Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g. cancer and cancer metastasis, are of formula (II), where A 1 is C—X 1 or N; Q 1 is -A 2 =A 3 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is -A 4 =A 5 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 2-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 2-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:

  具有高抑制血管新生活性的化合物，可用作治疗和预防涉及病理性血管新生的疾病的有效药物，例如癌症和癌症转移，其化学式为（II），其中A1为C-X1或N；Q1为-A2=A3-，或从-O-，-S-和-N（R10）中选择的杂原子；Q2为-A4=A5-，或从-O-，-S-和-N（R10）中选择的杂原子；前提是Q1和Q2不同时为杂原子；A2为C-X2或N，A3为C-X3或N，A4为C-X4或N，A5为C-X5或N；Y为C2-6烷基，C3-9环烷基，C2-7烯基，C2-7炔基，C2-6烷氧基，C2-7烯氧基，C2-7炔氧基或C1-6烷基硫；Z为氢原子，羟基，C1-6烷基，C3-9环烷基或-NR1R2；L从以下公式中选择：